Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05223088
Other study ID # TAOS-3B
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 31, 2021
Est. completion date April 30, 2024

Study information

Verified date January 2023
Source Fujian Cancer Hospital
Contact chen lu chuan, bachelor
Phone 13905022862
Email Luchuanchen@sina.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the clinical efficacy and safety of Tislelizumab combined with apatinib mesylate, oxaliplatin plus S1.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date April 30, 2024
Est. primary completion date April 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Age: 18-70 years of age - Histologically confirmed gastric adenocarcinoma was diagnosed in patients with locally advanced gastric cancer with tumor volume >5cm Borrmann III, Borrmann IV and BulkyN according to AJCC Version 8 - measurable lesions at least should be detected by CT/MRI examination in accordance with the RECIST1.1. - ECOG(Eastern Cooperative Oncology Group)PS(Performance Status):0-1 scores; - No previous surgical treatment, anti-tumor chemoradiotherapy/immunotherapy was performed - Preoperative endoscopic examination confirmed no positive peritoneal implantation metastasis and exfoliated cells - the expected survival time is more than 6 months - the main organ function is normal, which should meet the following criteria: 1. HB= 9g/dL 2. ANC=1.5×109/L 3. PLT=100×109/L 4. TBIL=1.5 normal upper limit ULN ;or TBIL>ULN but BIL=ULN 5. ALT and AST=2.5 ULN(ALT or AST =5×ULN was allowed in patients with liver metastasis) 6. Cr=1.5 ULN,CCR(creatinine clearance rate)=60ml/min(Cockcroft-Gault formula) 7. Good coagulation function, defined as international standardized ratio (INR) or prothrombin time (PT) =1.5 ULN 8. Normal thyroid function, defined as thyroid stimulating hormone (TSH) within the normal range.If the baseline TSH is outside the normal range, subjects with total T3 (or FT3) and FT4 within the normal range may be enrolled; 9. The myocardial enzyme profile is within the normal range (if the investigator comprehensively determines that the simple laboratory abnormality is not clinically significant, it is allowed to be included in the group - For women of reproductive age, a urine or serum pregnancy test with negative results should be performed within 3 days prior to receiving the first study drug administration (day 1 of cycle 1).If a urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is requested.Women of childbearing age were defined as at least 1 year after menopause or having undergone surgical sterilization or hysterectomy;? - If there is a risk of conception, all subjects (both men and women) are required to use a contraceptive with an annual failure rate of less than 1% throughout the treatment period up to 120 days after the last study drug (or 180 days after the last chemotherapeutic drug) - participants is willing to participate in this study, sign the informed consent, have good compliance, cooperate with follow-up. Exclusion Criteria: - Diagnosis of malignant diseases other than gastric cancer within 5 years prior to first administration (excluding radical basal cell carcinoma of the skin, squamous carcinoma of the skin, and/or radical resectable carcinoma in situ); - Significant clinical bleeding symptoms or clear bleeding tendency, such as gastrointestinal bleeding, hemorrhagic gastric ulcer or vasculitis, etc. occurred within 3 months before enrollment. If fecal occult blood was positive at baseline, reexamination could be performed; if it was still positive after reexamination, gastroscopy was required - Prior treatment: anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or drugs that target another stimulating or co-inhibiting T-cell receptor (e.g., CTLA-4, OX-40, CD137); - A history of immunodeficiency, including HIV testing positive. - Is currently participating in an interventional clinical study or has been treated with another study drug or study device in the 4 weeks prior to initial dosing. - Patients who had a history of cardiovascular and cerebrovascular diseases and were still taking thrombolytic drugs or anticoagulants orally. - HER2 positive is known; - Patients with previous gastrointestinal perforation, abdominal abscess or recent intestinal obstruction (within 3 months) or imaging or clinical symptoms suggesting intestinal obstruction;

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tislelizumab
Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 3-6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
Apatinib Mesylate
Participants will receive apatinib, 250mg, qd,every 3 weeks for 2-5 weeks.
oxaliplatin
Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 3-6 weeks.
Tegafur
Participants will receive Tegafur, day 1-14 of every 3 weeks for 3-6 weeks.

Locations

Country Name City State
China Fujian cancer hospital Fuzhou

Sponsors (1)

Lead Sponsor Collaborator
Fujian Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total/moderate tumor regression rate under pathology Primary tumor or lymph node surgery specimen pathological examination without residual tumor cell 4 weeks after surgery
Secondary Objective Response Rate (ORR) Objective Response Rate Determine the tumor shrinkage rate, tumor boundary and the adhesion of tumor At the end of Cycle 3 (each cycle is 21 days)
Secondary Overall survival (OS) Defined from date of Signing ICF to date of first documentation of death from any cause or censored at the date of the last follow-up.
Defined from date of Signing ICF to date of first documentation of death from any cause or censored at the date of the last follow-up.
Defined from date of Signing ICF to date of first documentation of death from any cause or censored at the date of the last follow-up.
Defined from date of Signing ICF to date of first documentation of death from any cause or censored at the date of the last follow-up.
every 3 months (up to 24 months) ]
See also
  Status Clinical Trial Phase
Recruiting NCT05848011 - A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT05161572 - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Phase 2
Recruiting NCT06165900 - Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC Phase 2
Recruiting NCT06120127 - Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence Phase 2
Recruiting NCT06262581 - Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery Phase 2
Recruiting NCT05176002 - Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. Phase 1/Phase 2
Not yet recruiting NCT05909137 - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Recruiting NCT04500990 - MRI DWI None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Prospective Observational Study
Not yet recruiting NCT04372732 - Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC
Completed NCT02692976 - Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients Phase 2
Completed NCT03763630 - MAPS & ITEC Cohorts: 6-8 Years Follow-up Phase 2
Not yet recruiting NCT06012318 - Dynamic Follow-up of Symptoms Based on Patient-reported Outcomes in Immunotherapy for Esophageal Cancer: a Prospective Multicentre Cohort Study (SPRING)
Not yet recruiting NCT05479240 - Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer Phase 2
Recruiting NCT04711330 - Response and Toxicity Prediction by Microbiome Analysis After Concurrent Chemoradiotherapy
Recruiting NCT05515796 - Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors Phase 2
Recruiting NCT03683407 - Effect of Chemotherapy on TMB in NSCLC
Recruiting NCT03701607 - Effect of Chemotherapy on PD-L1 in NSCLC
Completed NCT03357861 - Cancer Patients Treated With Immunotherapy in Intensive Care Unit
Completed NCT05657262 - Effect of Z Technıque on Pain, Comfort, Symptoms in Ummunotherapy Areas N/A
Recruiting NCT05621356 - Monitoring Allergen Immunotherapy in Allergic Rhinitis